title: Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura.
abstract: Anti-D was evaluated in 8 RhD positive patients (6 males, 2 females) aged 2-21 years (mean 10 years) with Idiopathic Thrombocytopenic Purpura (ITP). Five patients with chronic ITP and 3 patients with acute ITP were administered Anti-D in the dosage of 50 micrograms/kg intramuscularly (IM) for 3 consecutive days. One patient of chronic ITP received two courses of Anti-D. Patients were followed up for 7 to 16 months (mean 9 months). All three cases of acute ITP had a complete response and are in remission between 3 to 12 months of follow up. Two of five cases of chronic ITP had a partial response. Rise in platelet count was observed within 72-124 hours, and duration of response varied between 10 to 15 days. None of these patients had any significant side effects of anti-D immunoglobulin therapy. Intramuscular administration of Anti-D is safe, effective and low cost alternative to IVIgG in the treatment of acute ITP.
authors.affiliation: Department of Hematology, All India Institute of Medical Sciences, New Delhi.
authors.forename: L
authors.initials: L
authors.lastname: Krishnamurti
authors.forename: V D
authors.initials: VD
authors.lastname: Charan
authors.forename: N
authors.initials: N
authors.lastname: Desai
authors.forename: H
authors.initials: H
authors.lastname: Pati
authors.forename: V P
authors.initials: VP
authors.lastname: Choudhry
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*
chemical_list: D018029:Rho(D) Immune Globulin